Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: A randomized controlled trial

Obstetrics and Gynecology

Volumn 113, Issue 2 PART 1, 2009, Pages 285-292

  Caritis, Steve N ^a,b   Rouse, Dwight J ^b   Peaceman, Alan M ^b   Sciscione, Anthony ^b   Momirova, Valerija ^b   Spong, Catherine Y ^b   Iams, Jay D ^b   Wapner, Ronald J ^b   Varner, Michael ^b   Carpenter, Marshall ^b   Lo, Julie ^b   Thorp, John ^b   Mercer, Brian M ^b   Sorokin, Yoram ^b   Harper, Margaret ^b   Ramin, Susan ^b   Anderson, Garland ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b 300 Halket Street ^*

Author keywords

[No Author keywords available]

Indexed keywords

17 ALPHA HYDROXYPROGESTERONE CAPROATE; HEXANOIC ACID DERIVATIVE; PLACEBO; UNCLASSIFIED DRUG; 17-ALPHA-HYDROXY-PROGESTERONE CAPROATE; GESTAGEN; HYDROXYPROGESTERONE CAPROATE; PROGESTERONE DERIVATIVE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FETUS WASTAGE; GESTATION PERIOD; HUMAN; MULTICENTER STUDY; MULTIPLE PREGNANCY; PREMATURE LABOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; INTRAMUSCULAR DRUG ADMINISTRATION; PREGNANCY; PREMATURITY; RISK; TREATMENT FAILURE;

ADULT; FEMALE; HUMANS; HYDROXYPROGESTERONES; INJECTIONS, INTRAMUSCULAR; PREGNANCY; PREMATURE BIRTH; PROGESTINS; RISK; TREATMENT FAILURE; TRIPLETS;

EID: 60549095446     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e318193c677     Document Type: Article

References (22)

1. Alexander GR, Salihu HM. Perinatal outcomes of singleton and multiple births in the United States, 1995-98. In: Blick-stein I, Keith G, editors. Multiple pregnancy. London (UK): Taylor and Francis; 2005. p. 3-10.
2. Mathews TJ, MacDorman MF. Infant mortality statistics from the 2003 period linked birth/infant death data set. Natl Vital Stat Rep 2006;54:1-29.
3. Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate [published erratum appears in N Engl J Med 2003;349:1299]. N Engl J Med 2003;348:2379-85.
4. Rouse DJ, Caritis SN, Peaceman AM, Sciscione A, Thom EA, Spong CY, et al. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med 2007;357:454-61.
5. Carey JC, Klebanoff MA, Hauth JC, Hillier SL, Thom EA, Ernest JM, et al. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 2000;342:534-40.
6. Wei LJ, Lachin JM. Properties of the urn randomization in clinical trials [published erratum appears in Control Clin Trials 1989;10:126]. Control Clin Trials 1988;9:345-64.
7. Cnaan A, Ryan L. Survival analysis in natural history studies of disease. Stat Med 1989;8:1255-68.
8. Wei LJ, Lachin JM. Two-sample asymptotically distribution-free tests for incomplete multivariate observations. J Am Stat Assoc 1984;79:653-61.
9. Lan KK, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659-63.
10. Ou CW, Orsino A, Lye SJ. Expression of connexin-43 and connexin-26 in the rat myometrium during pregnancy and labor is differentially regulated by mechanical and hormonal signals. Endocrinology 1997;138:5398-407.
11. Shynlova O, Mitchell JA, Tsampalieros A, Langille BL, Lye SJ. Progesterone and gravidity differentially regulate expression of extracellular matrix components in the pregnant rat myome-trium. Biol Reprod 2004;70:986-92.
12. Davis ME, Wied GL. 17-Alpha-hydroxyprogresterone-caproate: a new substance with prolonged progestational activity; a comparison with chemically pure progesterone. J Clin Endocrinol Metab 1955;15:923-30.
13. Reifenstein EC Jr. Introduction of marked as well as prolonged biologic activity by esterification; 17-alpha-hydroxyprogester-one caproate, a unique progestational compound. Fertil Steril 1957;8:50-79.
14. Johnson JW, Austin KL, Jones GS, Davis GH, Efficacy of 17alpha-hydroxyprogesterone caproate in the prevention of premature labor. N Engl J Med 1975;293:675-80.
15. Keirse MJ. Progestogen administration in pregnancy may prevent preterm delivery. Br J Obstet Gynaecol 1990;97:149-54.
16. Attardi BJ, Zeleznik A, Simhan H, Chiao JP, Mattison DR, Caritis SN, et al. Comparison of progesterone and glucocor-ticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins. Am J Obstet Gynecol 2007;197: 599.e1-7.
17. Reijnders FJ, Thomas CM, Doesburg WH, Rolland R., Endocrine effects of 17 alpha-hydroxyprogesterone caproate during early pregnancy: a double-blind clinical trial. Br J Obstet Gynaecol 1998;95:462-8.
18. Meeting of the Advisory Committee for Reproductive Health Drugs, August 29, 2006.Available at: www.fda.gov/ohrms/ dockets/ac/06/slides/2006-4227S1- index.htm. Retrieved November 7, 2008.
19. Brancazio LR, Murtha AP, Heine RP. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003;349:1087-8.
20. Thiery M, Baines CJ, Kierse MJ, editors. The development of methods for inducing labour. In: Chalmers I, Enkin M, Kierse MJ, editors. Effective care in pregnancy and childbirth. Oxford (UK): Oxford University Press; 1989. p. 969-80.
21. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Menacker F, Kirmeyer S, et al. Births: final data for 2004. Natl Vital Stat Rep 2006; 55: 1-101.
22. Rittenberg C, Sullivan S, Istwan N, Rhea D, Stanziano G, Newman R. Clinical characteristics of women prescribed 17 alpha-hydroxyprogesterone caproate in the community setting. Am J Obstet Gynecol 2007; 197: 252.e1-4.